À̽ÄÇü Á¦¼¼µ¿±â(ICD) ½ÃÀå : Á¦Ç° À¯Çüº°, ÀåÄ¡ À¯Çüº°, NYHA Ŭ·¡½º À¯Çüº°, ÃÖÁ¾ »ç¿ëÀÚº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2024-2032³â)
Implantable Cardioverter Defibrillators Market, By Product Type, By Device type, By NYHA Class Type, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
»óǰÄÚµå : 1455684
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2024³â 03¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 284 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,518,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,464,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 7,855,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

À̽ÄÇü Á¦¼¼µ¿±â(ICD) ½ÃÀå ±Ô¸ð´Â 2023³â 39¾ï 4,556¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ 7.41% ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ICD ½ÃÀå - ½ÃÀå ¿ªÇÐ

±â¼ú ¹ßÀü°ú Á¦Ç° Çõ½ÅÀº ½ÃÀå ¼ö¿ä¸¦ ÃËÁøÇÕ´Ï´Ù.

MedtronicÀÇ Epsila EV MRI SureScan ¹× Aurora Extravascular(EV)-ICD MRI SureScan°ú °°Àº ±â¼ú ¹ßÀü°ú Á¦Ç° ¹ß¸íÀº ÇÕº´Áõ °¨¼Ò ¹× ¼³Ä¡ ±â¼ú °³¼±°ú °°Àº À¯¸ÁÇÑ ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ÇöÀç ÁøÇà ÁßÀÎ ±â¼ú ¹ßÀü, ƯÈ÷ ÃÖ±Ù ¸î ³âµ¿¾È ¸ñ°ÝµÈ ICDÀÇ ³î¶ó¿î ¼º°ø·üÀº ½ÃÀåÀÇ Ãß°¡ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 8¿ù, ¸ÞµåÆ®·Î´Ð PLC´Â °©ÀÛ½º·± ½ÉÀ帶ºñ¸¦ ¿¹¹æÇϱâ À§ÇÑ Çõ½ÅÀûÀÎ Àúħ½ÀÀû Á¦¼¼µ¿±â ÀÓÇöõÆ®ÀÎ ¸ÞµåÆ®·Î´Ð EV ICD ½Ã½ºÅÛÀÇ È¿´ÉÀ» ÀÔÁõÇÏ´Â Àӻ󿬱¸¸¦ ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ Ç÷°ü¿Ü ICD ½Ã½ºÅÛÀº ÁÖ¿ä ±¸¼º¿ä¼Ò¸¦ ¿ÞÂÊ °Üµå¶ûÀÌ ¾Æ·¡¿¡ ¹èÄ¡Çϰí Ȧµå¾÷ ÆäÀÌ½Ì ¿ä¹ýÀ» ÅëÇØ Áøµ¿À» ¾ïÁ¦ÇÏ°í ºó¸ÆÀ» ¿¹¹æÇϸç Á¦¼¼µ¿ ¼îÅ©¸¦ ÇÇÇÒ ¼ö ÀÖµµ·Ï ȯÀÚ¸¦ µ½½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϰí À§ÇèÀ» ÁÙÀÌ¸ç ½ÉÀå Ä¡·á ±â¼ú ¹ßÀü¿¡ ´ëÇÑ ¾÷°èÀÇ ³ë·ÂÀ» °­Á¶ÇÔÀ¸·Î½á ½ÃÀå¿¡ Å« ±â¿©¸¦ Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·á ½Ã¼³¿¡¼­ ICDÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ ½ÃÀå È®´ëÀÇ ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 12¿ù Ŭ¸®ºí·£µå Ŭ¸®´Ð(Cleveland Clinic)Àº ±¹Á¦ ÀÓ»ó½ÃÇèÀÇ ÀÏȯÀ¸·Î ¼¼°è ÃÖÃÊ·Î µÎ ¸íÀÇ È¯ÀÚ¿¡°Ô ¹«½ÉÀå Á¦¼¼µ¿±â ½Ã½ºÅÛÀ» ¼º°øÀûÀ¸·Î À̽ÄÇÏ´Â µ¥ ¼º°øÇß½À´Ï´Ù. ±× °á°ú, ÀÌ Áö¿ª¿¡¼­ ICDÀÇ º¸±Þ°ú ½ÉÀå ¸®µë Àå¾ÖÀÇ À¯º´·ü Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ICD ½ÃÀå - ÁÖ¿ä ÀλçÀÌÆ®

´ç»çÀÇ ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®°¡ °øÀ¯ÇÑ ºÐ¼®¿¡ µû¸£¸é, ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2024-2032) µ¿¾È ¸Å³â ¾à 7.41%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Á¦Ç° À¯Çüº°·Î´Â °æÁ¤¸Æ ICD°¡ 2023³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

±â±â À¯Çüº°·Î´Â 2023³â ¾ç½É½Ç ±â±â°¡ ÁÖ¿ä À¯ÇüÀ¸·Î ºÎ»óÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

NYHA Ŭ·¡½ºº°·Î´Â 2023³â NYHA Ŭ·¡½º II°¡ ÁÖ¿ä À¯ÇüÀ¸·Î ºÎ»óÇÒ °ÍÀÔ´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2023³â ¸ÅÃâ 1À§

À̽ÄÇü Á¦¼¼µ¿±â ½ÃÀå - ¼¼ºÐÈ­ ºÐ¼® :

ICD ¼¼°è ½ÃÀåÀº Á¦Ç° À¯Çü, ÀåÄ¡ À¯Çü, NYHA Ŭ·¡½º À¯Çü, ÃÖÁ¾ »ç¿ëÀÚ ¹× Áö¿ªÀ» ±âÁØÀ¸·Î ¼¼ºÐÈ­µË´Ï´Ù.

½ÃÀåÀº Á¦Ç° À¯Çü¿¡ µû¶ó °æÁ¤¸Æ ICD(T-ICD)¿Í ÇÇÇÏ ICD ºÎ¹®(S-ICD)·Î ºÐ·ùµÇ¸ç, 2023³â¿¡´Â T-ICD ºÎ¹®ÀÌ ½ÃÀå¿¡¼­ Áö¹èÀûÀÎ À§Ä¡¸¦ Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ¿ìÀ§´Â T-ICD°¡ »ý¸íÀ» À§ÇùÇÏ´Â ½É½Ç ºÎÁ¤¸ÆÀ» °ü¸®Çϰí ħ½ÀÀû ¼ö¼ú°ú °ü·ÃµÈ ÇÕº´Áõ ¹× ÀÇ·á ºñ¿ëÀ» ÁÙÀÌ´Â µ¥ ÀÖ¾î ±ÍÁßÇÑ ÀÌÁ¡À» Á¦°øÇϱ⠶§¹®À̸ç, T-ICD´Â ¿µ±¸ ¹Úµ¿, ½ÉÀå À絿±âÈ­ Ä¡·á(CRT), Ç×ºó¸Æ ¹Úµ¿°ú °°Àº ±â´ÉÀ» ÅëÇØ ½É½Ç¼¼µ¿(VF) ¹× ½É½Ç¼¼µ¿(VF) ¹× ½É½Çºó¸Æ(VT) ȯÀÚÀÇ ¿ä±¸¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù.

ÀÌ ½ÃÀåÀº ÀåÄ¡ À¯Çü¿¡ µû¶ó ´ÜÀÏ Ã¨¹ö ICD, ÀÌÁß Ã¨¹ö ICD, ¾ç½É½Ç ÀåÄ¡ µî ¼¼ °¡Áö·Î ºÐ·ùµÇ¸ç, 2023³â¿¡´Â ¾ç½É½Ç ÀåÄ¡ ºÎ¹®ÀÌ ½ÃÀå ¸®´õ·Î ºÎ»óÇß½À´Ï´Ù. ½ÉÀå µ¹¿¬»ç Áõ°¡, ½É¹ÚÁ¶À²±â¿Í Á¦¼¼µ¿±â·Î¼­ÀÇ ÀÌÁß ±â´É µîÀÇ ¿äÀÎÀÌ CRT-D ÀåÄ¡¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À¯ÇØÇÑ »óŸ¦ ½Å¼ÓÇÏ°Ô º¸°íÇÏ´Â ±â´É°ú Çâ»óµÈ ÆäÀÌ½Ì ¼º´ÉÀÌ °áÇÕµÇ¾î »ç¸Á·ü °¨¼Ò¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÁÖ¿ä ±â¾÷µéÀº ÀÌ·¯ÇÑ ÀåÄ¡¸¦ °­È­ÇÏ´Â µ¥ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2019³â 3¿ù ¹ÙÀÌ¿ÀÆ®·Î´Ð(BIOTRONIK)Àº À¯·´ ½ÃÀå¿¡¼­ ¼¼°è¿¡¼­ °¡Àå ÀÛÀº CRT-D ¹× ICD ÀåÄ¡¸¦ Ãâ½ÃÇßÀ¸¸ç, 3Å×½½¶ó Àü½Å MRI ½ºÄµ ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù. ¶ÇÇÑ MRI ȣȯ¼º, ºí·çÅõ½º ±â´É, 4±Ø ¸®µå µî ÀÌ ºÎ¹®ÀÇ ±â¼ú ¹ßÀüÀº äÅ÷üÀ» ³ôÀÏ ¼ö ÀÖ´Â ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2020³â 7¿ù Abbott´Â Â÷¼¼´ë ºí·çÅõ½º Áö¿ø CRT-D ¹× ICD¿¡ ´ëÇÑ FDA ½ÂÀÎÀ» ¹ßÇ¥Çß½À´Ï´Ù.

ICD ½ÃÀå - Áö¸®Àû ÅëÂû·Â

Áö¿ªÀûÀ¸·Î´Â ºÏ¹Ì, ¶óƾ¾Æ¸Þ¸®Ä«, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«¿¡ ºÐÆ÷µÇ¾î ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªµéÀº ºñÁî´Ï½º¸¦ °¡Á®¿À´Â ±¹°¡¿¡ µû¶ó ´õ ¼¼ºÐÈ­µË´Ï´Ù.

ICD ½ÃÀå - °æÀï ±¸µµ :

ICD ½ÃÀå¿¡ ÁøÃâÇÑ ±â¾÷µéÀº Á¦Ç°À» °­È­Çϱâ À§ÇØ ´Ù¾çÇÑ Àü·«À» äÅÃÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Àü·«¿¡´Â ÃÖ¼Ò Ä§½ÀÀû ½Ã¼úÀ» °¡´ÉÇÏ°Ô ÇÏ´Â ¼ÒÇüÈ­, ¹èÅ͸® ¼ö¸í ¿¬Àå µî ±â±âÀÇ È¿°ú¿Í ȯÀÚ ¿¹Èĸ¦ °³¼±Çϱâ À§ÇÑ ±â¼ú ¹ßÀüÀÌ Æ÷ÇԵ˴ϴÙ. ¶ÇÇÑ, °¢ ¾÷üµéÀº ´Éµ¿ÀûÀΠȯÀÚ °ü¸®¿Í µ¥ÀÌÅÍ ±â¹Ý ÀÇ»ç°áÁ¤À» ÃËÁøÇϱâ À§ÇØ ¿ø°Ý ¸ð´ÏÅ͸µ ±â´ÉÀ» °®Ãá Áö´ÉÇü ±â±â °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ÀÇ·á Á¦°ø¾÷ü ¹× ¿¬±¸ ±â°ü°úÀÇ Çù¾÷Àº Áö¼ÓÀûÀÎ ±â¼ú Çõ½ÅÀ» ÃËÁøÇϰí ÃֽŠÀÇ·á ¹ßÀüÀ» ÅëÇÕÇÏ´Â µ¥ ÀÖ¾î ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ¶ÇÇÑ, ±ÔÁ¦ Áؼö¿Í ¾ö°ÝÇÑ Ç°Áú ±âÁØ Áؼö¸¦ À§ÇÑ ³ë·ÂÀº ¼ÒºñÀÚÀÇ ½Å·Ú¸¦ °­È­ÇÏ°í ½ÃÀå ħÅõ¸¦ ÃËÁøÇÏ¿©À̽ÄÇü Á¦¼¼µ¿±â(ICD) ½ÃÀåÀÇ Áö¼ÓÀûÀÎ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå À̽ÄÇü Á¦¼¼µ¿±â(ICD) ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ICD ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå ICD ¾÷°è Á¶»ç

Á¦5Àå À̽ÄÇü Á¦¼¼µ¿±â(ICD) ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

Á¦6Àå À̽ÄÇü Á¦¼¼µ¿±â(ICD) ½ÃÀå ±¸µµ

Á¦7Àå À̽ÄÇü Á¦¼¼µ¿±â(ICD) ½ÃÀå - Á¦Ç° À¯Çüº°

Á¦8Àå À̽ÄÇü Á¦¼¼µ¿±â(ICD) ½ÃÀå - µð¹ÙÀ̽º À¯Çüº°

Á¦9Àå À̽ÄÇü Á¦¼¼µ¿±â(ICD) ½ÃÀå - NYHA Ŭ·¡½º ŸÀÔº°

Á¦10Àå À̽ÄÇü Á¦¼¼µ¿±â(ICD) ½ÃÀå - ÃÖÁ¾»ç¿ëÀÚº°

Á¦11Àå À̽ÄÇü Á¦¼¼µ¿±â(ICD) ½ÃÀå - Áö¿ªº°

Á¦12Àå ÁÖ¿ä º¥´õ ºÐ¼® - ICD ¾÷°è

Á¦13Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Implantable cardioverter defibrillators Market size was valued at USD 3,945.56 Million in 2023, expanding at a CAGR of 7.41% from 2024 to 2032.

The implantable cardioverter defibrillator (ICD) is an electronic medical device utilized for monitoring and controlling heart rhythms in individuals vulnerable to life-threatening arrhythmias like ventricular tachycardia as well as ventricular fibrillation. Market growth drivers encompass technological advancements, increasing occurrences of sudden cardiac arrest, rising public awareness, and supportive governmental and healthcare organizational policies. Emerging players' innovation efforts, exemplified by MicroPort Scientific Corporation's receipt of a CE mark for its INVICTA line of defibrillation leads in July 2022, also contribute to market expansion. With the escalating prevalence of cardiovascular diseases (CVDs), the demand for advanced cardiac care solutions, including ICDs, is anticipated to surge, presenting opportunities for healthcare sector expansion and advancements.

Implantable cardioverter defibrillators Market- Market Dynamics

Technological progress and product innovations to propel market demand

Technological progress and product inventions, including Medtronic's Epsila EV MRI SureScan along with Aurora Extravascular (EV)-ICD MRI SureScan, offer promising solutions with reduced complications and improved placement techniques. The ongoing technological advancements, particularly the commendable success rates witnessed in recent years for ICDs, are expected to propel further market growth. For instance, in August 2022, Medtronic PLC presented clinical research demonstrating the efficacy of an innovative minimally invasive defibrillator implant, the Medtronic EV ICD system, aimed at preventing sudden cardiac arrest. This extravascular implantable defibrillator scheme, with its main component located beneath the left armpit, delivers holdup pacing therapy to reduce vibrations, prevent tachycardia, and assist patients in avoiding defibrillation shock. Such advancements significantly contribute to the market by enhancing patient outcomes, mitigating risks, and highlighting the industry's commitment to advancing cardiac care technologies. Moreover, the increasing adoption of ICDs within healthcare facilities is poised to be a significant market expansion driver. For instance, in December 2021, Cleveland Clinic successfully conducted leadless pacemaker defibrillator system implants in the first two patients globally as part of an international clinical trial. This innovative device, designed to address both low and elevated heart rates, integrates leadless pacemaker End User with subcutaneous ICDs. Consequently, the growing acceptance of implantable defibrillators and the rising prevalence of cardiac rhythm disorders in the region are expected to drive market growth.

Implantable cardioverter defibrillators Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.41% over the forecast period (2024-2032)

Based on product type segmentation, transvenous implantable cardioverter-defibrillators was predicted to show maximum market share in the year 2023

Based on Device type segmentation, biventricular devices was the leading type in 2023

Based on NYHA Class Type segmentation, NYHA Class II was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Implantable cardioverter defibrillators Market- Segmentation Analysis:

The Global Implantable cardioverter defibrillators Market is segmented on the basis of Product Type, Device type, NYHA Class Type, End User, and Region.

The market is divided into two categories based on product type: transvenous implantable cardioverter-defibrillators (T-ICDs) and subcutaneous implantable cardioverter defibrillator segments (S-ICDs) based on product type. In 2023, the T-ICDs segment held the dominant position in the market. This dominance is attributed to the valuable advantages offered by T-ICDs in managing life-threatening ventricular arrhythmias, as well as in reducing procedural complications and medical costs associated with invasive surgeries. T-ICDs cater to the needs of patients with ventricular fibrillation (VF) and ventricular tachycardia (VT) through features like permanent pacing, cardiac resynchronization therapy (CRT), and anti-tachycardia pacing.

The market is divided into three categories based on Device type: single-chamber ICDs, dual-chamber ICDs, and biventricular devices. In 2023, the biventricular devices segment emerged as the market leader. Factors such as the increasing prevalence of sudden cardiac deaths and its dual functionality as a pacemaker and a defibrillator are anticipated to drive the demand for CRT-D devices. The ability to promptly report adverse conditions, combined with enhanced pacing performance, contributes to reducing mortality rates. Moreover, major players are concentrating on enhancing these devices. For instance, in March 2019, BIOTRONIK introduced the smallest CRT-D and ICD devices globally in the European market, which were approved for 3 Tesla full-body MRI scans. Additionally, technological advancements in this segment, such as MRI compatibility, Bluetooth capability, and quadripolar leads, have the potential to enhance adoption rates. For example, in July 2020, Abbott announced FDA approval for its next-generation Bluetooth-enabled CRT-D and ICD devices.

Implantable cardioverter defibrillators Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

Implantable cardioverter defibrillators Market- Competitive Landscape:

Companies operating in the implantable cardioverter defibrillators (ICD) market are employing various strategies to enhance their offerings. These strategies encompass technological advancements aimed at improving device efficacy and patient outcomes, such as miniaturization to enable less invasive procedures and prolonging battery life. Furthermore, companies are concentrating on the development of intelligent devices equipped with remote monitoring capabilities to facilitate proactive patient management and data-driven decision-making. Collaborations with healthcare providers and research institutions play a pivotal role in fostering continuous innovation and ensuring the integration of the latest medical advancements. Additionally, efforts directed towards regulatory compliance and adherence to stringent quality standards serve to reinforce consumer trust and enhance market penetration, thereby fostering sustained growth in the ICD market.

Recent Developments:

In June 2023, BIOTRONIK SE & Co. KG entered into a partnership with Royal Philips aimed at expanding the latter's admission to cardiovascular devices. Philips SymphonySuite, the primary entity solution available for cardiovascular care in Ambulatory Surgery Centers (ASCs) and office-based labs, stands as a testament to this collaborative effort.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Abbott

Medtronic

BIOTRONIK SE & Co. KG

Boston Scientific Corporation

MicroPort Scientific Corporation.

LivaNova PLC.

Others

GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032

GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET, BY DEVICE TYPE- MARKET ANALYSIS, 2019 - 2032

GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET, BY NYHA CLASS TYPE- MARKET ANALYSIS, 2019 - 2032

GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

Table of Contents

1.Implantable cardioverter defibrillators Market Overview

2.Executive Summary

3.Implantable cardioverter defibrillators Key Market Trends

4.Implantable cardioverter defibrillators Industry Study

5.Implantable cardioverter defibrillators Market: COVID-19 Impact Analysis

6.Implantable cardioverter defibrillators Market Landscape

7.Implantable cardioverter defibrillators Market - By Product Type

8.Implantable cardioverter defibrillators Market - By Device Type

9.Implantable cardioverter defibrillators Market - By NYHA Class Type

10.Implantable cardioverter defibrillators Market - By End Use

11.Implantable cardioverter defibrillators Market- By Geography

12.Key Vendor Analysis- Implantable cardioverter defibrillators Industry

13.360 Degree Analyst View

14.Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â